Reduction of Bacterial Burden and Pain in Chronic Wounds Using a New Polyhexamethylene Biguanide Antimicrobial Foam Dressing-Clinical Trial Results

Abstract

PHMB foam dressing successfully reduced chronic wound pain and bacterial burden.

Chlorhexidine gluconate or polyhexamethylene biguanide disc dressing to reduce the incidence of central-line-associated bloodstream infection: a feasibility randomized controlled trial (the CLABSI trial)

“…The disc has been shown to reduce biofilms in wounds 12 and reduce wound pain and wound size. 13 More importantly, PHMB has been shown to inhibit the growth of Staphylococcus aureus 14 , a common and serious pathogen in CLABSI. To date, there are no randomised controlled trials (RCTs) comparing the effectiveness of the PHMB disc with other products to reduce CLABSI; nor has the CHG disc dressing been tested in head-to-head studies with any other antimicrobial dressing.…”

The Effect of Polyhexamethylen Biguanide on Microorganisms in Root Canal

“…PHMB je biocid iz porodice bisbigvanida sa širo-kim spektrom uporabe -dezinficijens je za površine, objekte i instrumente. Također se rabi u tretmanima rana (11), za poticanje zarastanja kroničnih rana (12), u otopinama za ispiranje usne šupljine (13) te u onima za čuvanje i ispiranje kontaktnih leća (14).…”

“…PHMB is biocide of bisbiguanide familiy with broad spectrum of use; disinfectant for surfaces, objects, instruments. It is also used in wound treatments (11), promoting wound healing (12), in mouthwash formulations (13) and in soft lenses care solutions (14).…”

Negative pressure wound therapy with instillation (NPWTi): Current status, recommendations and perspectives in the context of modern wound therapy.

“…Sibbald et al conducted a multicenter, prospective, randomized clinical trial comparing the effectiveness of polyhexamethylene biguanide (PHMB) foam dressing and non-antimicrobial foam in the treatment of chronic wounds. 60 Bacterial bioburden was significantly reduced in PHMB foam group (P = 0,016). In addition, pain reduction was revealed as a statistically significant result at 2 weeks and at 4 weeks of the therapy in the group of PHMB management.…”